GNVC News Alert Genvec Inc (GNVC) 1.83 12/16/2014 22:55:43

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genvec Inc (GNVC) 1.83 $GNVC

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 11:45AM CST

EXXI: 2.60 (+0.15), EOX: 0.97 (+0.04), VTAE: 19.86 (-0.23), SN: 7.15 (+0.67), PVA: 4.78 (+0.27), ORPN: 6.54 (-0.07), LPI: 7.70 (+0.31), SNMX: 5.19 (-0.09), UAL: 61.63 (-2.41), RDUS: 26.30 (+1.20), GNVC: 1.83 (-0.04), GDP: 4.14 (+0.09), SFY: 2.98 (+0.35), BORN: 1.41 (-0.02), REN: 1.03 (-0.01), SCYX: 10.10 (+0.06), VGGL: 3.43 (+0.28), CMGE: 18.68 (-0.56), SLCA: 24.06 (+0.37), OAS: 14.23 (+2.01)

GenVec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:00AM CST

GNVC: 1.83 (-0.04)

GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 1.83 (-0.04), NVS: 91.65 (+0.01)

Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium
PR Newswire - Tue Nov 11, 6:30AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that data exploring the immune responses generated by its vaccine candidate, GV2311, were presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium being held in South Africa. These data were presented by Dr. Teresa R. Johnson, Chair of the Microbiology and Immunology Department of the Edward College of Osteopathic Medicine in Virginia. GV2311 utilizes GenVec's proprietary gorilla adenovector platform. These vectors are designed to produce superior performance in gene-based vaccines, including induction of durable high-level antibody responses as well as high-level T cell responses. They have also been shown to induce increased immune responses on repeat administration.
GNVC: 1.83 (-0.04)

GenVec Achieves Milestone In Hearing And Balance Collaboration
PR Newswire - Wed Nov 05, 6:15AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved a milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. Novartis has dosed the first patient in a clinical study to assess the safety, tolerability, and efficacy of intra-labyrinthine (IL) CGF166 in patients with severe hearing loss. Under the terms of the collaboration agreement this triggers a $3 million milestone payment to GenVec.
GNVC: 1.83 (-0.04), NVS: 91.65 (+0.01)

Quinterol Mallette Appointed to GenVec Board Of Directors
PR Newswire - Fri Oct 31, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Quinterol J. Mallette, M.D. as a director of the company. In addition, Dr. Mallette was appointed to the board's audit committee.
GNVC: 1.83 (-0.04)

Zola P. Horovitz To Retire From GenVec Board
PR Newswire - Mon Oct 20, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.
GNVC: 1.83 (-0.04)

GenVec Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 12, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company reported a net loss of $2.6 million or $0.17 per share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per share on revenues of $2.0 million in the same period in the prior year. GenVec ended the second quarter of 2014 with $14.6 million in cash, cash equivalents, and liquid investments.
GNVC: 1.83 (-0.04)

GenVec Achieves Third Milestone In Hearing And Balance Collaboration
PR Newswire - Thu Feb 13, 5:00AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed effective on February 7, 2014 and this triggered a $2 million milestone payment to GenVec under the terms of the collaboration.
GNVC: 1.83 (-0.04), NVS: 91.65 (+0.01)

AutoGrid and Big Data Energy Services Announce Strategic Partnership to Deliver Demand Response (DR) Capabilities to Texas' Largest Electric Providers
Marketwire - Thu Dec 19, 6:32AM CST
AutoGrid Systems, a leader in innovative solutions for the electricity and energy industry, is proud to announce a strategic partnership with Big Data Energy Services (BDES), a cloud-based service provider and consulting firm, to deliver services and technology that will allow electricity providers to reduce the cost of power for their customers while mitigating the risk of sharply higher prices in tight energy markets.
SMSI: 0.85 (-0.05), GNVC: 1.83 (-0.04), LIVE: 2.59 (-0.08), SMRT: 14.37 (-0.09)

PowerCloud Systems and Common Sense Media Join Forces to Help Kids and Families Make Smart Choices Online
PR Newswire - Wed Dec 18, 7:00AM CST
PowerCloud Systems, a pioneer in cloud networking for the connected home, and Common Sense Media, the largest non-partisan, not-for-profit organization dedicated to helping kids thrive in a world filled with media and technology, today announced a partnership dedicated to facilitating easy access to age-appropriate Internet content in the home. PowerCloud Systems is the creator of Skydog(TM), the revolutionary home networking solution used by thousands of families to manage their connected lives by providing unprecedented visibility into, and management over, their home networks. This partnership will give Skydog users easy access to Common Sense Media's independent, age-based ratings and reviews of online media, based on developmental criteria from some of the nation's leading authorities, and provide a technical solution for the family to manage access to this media.
GNVC: 1.83 (-0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 92

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 93

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Harbour BioMed's LET003 Gets China's IND Green Light

Updated Category News Views 84

Muscle loss has become the awkward fact sitting beside every blockbuster obesity headline. Harbour BioMed's Nov. 18 announcement that China's National Medical Products Administration accepted its IND application for LET003 matters because the company is aiming directly at that problem: losing fat without giving away too much lean mass along the way. Acceptance Opens a...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 91

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Northstar's December Test: Metrics Over More Promises

Updated Category News Views 11

A shingle recycler earns its stripes when the machinery behaves, not when the slide deck does. Northstar Clean Technologies is putting Empower Calgary under a brighter light on December 1, pairing its third-quarter 2026 results with a comprehensive production update and a new set of operating metrics. For shareholders, especially those following OTCQB:ROOOF, this is the...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 35

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 72

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

MediPharm Labs: Strategic Steps for Enhanced Shareholder Value

Updated Category News Views 141

MediPharm Labs Announces Proxy Materials for Shareholder Meetings Toronto - MediPharm Labs Corp. (TSX: LABS) has filed comprehensive Management Information Circulars and proxy materials ahead of its upcoming Annual and Special Meeting. This meeting, pivotal for the future direction of the company, is set for June 16. Shareholders can expect to receive these materials...

Continue Reading
PRM Revitalizes Its Online Presence with Stylish Relaunch

Updated Category News Views 215

PRM Elevates Your Style with an Online Revamp In an exciting development for fashion enthusiasts, PRM, a trendsetting brand where luxury meets urban flair, has unveiled a newly revamped online store. This relaunch marks a significant transformation spearheaded with the expert assistance from industry professionals, aiming to elevate its presence in the European fashion...

Continue Reading
Why Companies Choose Altcoins Like ETH, SOL, and XRP Over Bitcoin

Updated Category News Views 188

Why Companies Are Opting for Altcoins in Their Treasury Strategies In recent times, publicly traded companies have increasingly embraced a wider array of cryptocurrencies beyond Bitcoin. Names like Ethereum, Solana, XRP, and Binance Coin are becoming commonplace in corporate treasuries. This trend reflects a significant shift in how businesses perceive and integrate these...

Continue Reading
Epson Launches Arm-Compatible Drivers for Advanced Scanning Solutions

Updated Category News Views 346

Epson's Commitment to Innovation in Scanning Technology Epson America, the top-selling scanner brand in the U.S., is proud to unveil Arm-compatible drivers for Windows in its extensive lineup of scanners. This groundbreaking step positions Epson as a leader in the scanning technology space, tailored for industries such as healthcare, finance, and enterprise solutions....

Continue Reading
Harnessing AI for Transformation: A Framework for Organizations

Updated Category News Views 240

Harnessing AI for Transformation: A Comprehensive Framework Artificial intelligence (AI) stands as one of the most revolutionary technologies in today’s world, yet many organizations grapple with moving from mere experiments to having a concrete enterprise strategy. A leading research and advisory firm has released a blueprint aimed at guiding both IT and business...

Continue Reading